Search Results
Your search for ,HIS matches 4477 pages
Showing 951 - 1000Towering Figure in Cancer Drug Development, José Baselga, MD, PhD, FASCO, Dies at Age 61
José Baselga, MD, PhD, FASCO, a global innovator in novel cancer therapeutics, led research efforts in his native country of Spain and in the United States, most notably as Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK). “My moment of recognition as an oncologist came early,...
An Oncologist and His Wife Share a Personal Cancer Story
Gastrointestinal oncologist John Marshall, MD, is well known for his candid observations about cancer treatment and research. In 2006, all the scientific intricacies and sociopolitical dramas of oncology coalesced in Dr. Marshall’s life when his 43-year-old wife, Liza, was diagnosed with breast...
Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries
Globally, breast cancer surpassed lung cancer as the most common cancer among women, with an estimated 2.3 million cases in 2020.1,2 Approximately 685,000 women will die of breast cancer in 2020 around the world. Approximately 24.5% of all cancers in women are breast cancer, and 15.5% of...
Lymph Node Collection Kit May Help Improve Outcomes After Lung Cancer Surgery
A lymph node collection kit may help surgeons attain complete resection and improve long-term survival after curative-intent lung cancer surgery, according to a recent study published by Matthew Smeltzer, PhD, and colleagues in JTO Clinical and Research Reports. Surgical resection is the most...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
Ravi Bellamkonda, PhD, Named Provost of Emory University
Emory University President Gregory L. Fenves, PhD, recently announced the appointment of biomedical scientist Ravi Bellamkonda, PhD, as the university’s next Provost and Executive Vice President for Academic Affairs, effective July 1, 2021. Dr. Bellamkonda returns to Emory after serving as Dean of...
Hans Clevers, MD, PhD, FAACR, Recognized With 2021 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Hans Clevers, MD, PhD, FAACR, at the virtual AACR Annual Meeting 2021, to be held April 10–15 and May 17–21. Dr. Clevers, who is...
Lydia Pace, MD, MPH: A Primary Care Physician on the Front Lines of Oncology, Both Nationally and Globally
Lydia Pace, MD, MPH, was inspired to a become a doctor by her grandfather, a general surgeon in New York City, who spoke effulgently of his career in medicine, and by her mother, a social worker who was equally passionate about her profession. A primary care physician, Dr. Pace developed an...
Prevent Cancer Foundation Awards Nine New Research Grants
The Prevent Cancer Foundation has announced funding for nine scientists who are researching cancer prevention and early detection. Each scientist is being awarded $100,000 for 2 years. Areas of focus include the pancreas, esophagus, liver, lungs, skin, prostate, colon-rectum, and blood/bone ...
Sachin Apte, MD, MS, MBA, Joins Huntsman Cancer Institute as Chief Clinical Officer
Huntsman Cancer Institute (HCI) and University of Utah (U of U) Health announced the appointment of Sachin Apte, MD, MS, MBA, as Chief Clinical Officer of HCI and Physician-in-Chief of the cancer hospital. “Dr. Apte will lead HCI’s clinical efforts at a time when we are poised to dramatically...
Gynecologic Oncology Leader Named at New Jersey’s Only NCI-Designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH) have named James K. Aikins, Jr, MD, FACOG, FACS, Chief of Gynecologic Oncology at Rutgers Cancer Institute and Chief of Gynecologic Oncology Services at RWJUH. He will also serve as Program Director for the...
Patrick Delaney Named New Executive Director of NCCN Foundation
The National Comprehensive Cancer Network (NCCN) has announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation. Mr. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society. ...
Winthrop P. Rockefeller Cancer Institute Appoints New Deputy Director
Cancer researcher Alan Tackett, PhD, has been named Deputy Director of the Winthrop P. Rockefeller Cancer Institute (Cancer Institute) at the University of Arkansas for Medical Sciences (UAMS). Dr. Tackett, who is noted for his research in cancer biomarker discovery, is Professor in the UAMS...
Groundbreaking Cancer Researcher Brian J. Druker, MD, Shows No Signs of Slowing Down
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with physician-scientist Brian J. Druker, MD, Director of the Knight Cancer Institute at Oregon Health & Science University, Portland. In 2009, Dr. Druker won the Lasker-DeBakey Clinical Medical Research ...
Evidence-Based Strategy for Improving Access to Colorectal Cancer Screening for Diverse Populations
A novel strategy of combining a drive-by flu vaccination clinic with an opportunity for participants to use a take-home fecal immunochemical test (FIT) increased access to colorectal screening among Black Americans during the COVID-19 pandemic. Results related to access to colorectal cancer...
Expert Point of View: Joshi J. Alumkal, MD
Invited discussant of the ACIS study, Joshi J. Alumkal, MD, leader of the Genitourinary Medical Oncology Section at the University of Michigan Rogel Cancer Center, noted that the toxicities were slightly higher with apalutamide plus abiraterone acetate/prednisone, including fatigue, hypertension,...
Cancer Cell Therapy Pioneer Carl June, MD, Named 2021 Dan David Prize Laureate
International cancer cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine and Director of the Center for Cellular Immunotherapies at Penn Medicine Abramson Cancer Center, has...
Physician-Patient Relationship: Sacred and Sacrosanct
There are many relationships we build at work in our entire lifetime. Some are good, a few are not, and many are somewhere in between. But of all the relationships we are fortunate enough to build, there is no relationship more valuable and gratifying than the one between a physician and a ...
Expert Point of View: Peter Schmid, MD, PhD
According to the invited discussant of UNIRAD,1Peter Schmid, MD, PhD, Lead of the Centre for Experimental Medicine at Barts Cancer Institute, Queen Mary University of London, it remains unclear whether or not everolimus plus hormone therapy is an effective adjuvant regimen for high-risk patients...
Repurposing Available Drugs for COVID-19: An Ongoing Initiative
As of this writing, no drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19, although several have received emergency use authorization and many others are being used off-label during the pandemic. In addition to searching for novel therapies, David...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO, and Shinichi Toyooka, MD
The ASCO Post reached out to Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, New Haven, for his thoughts on the LCMC3 trial of neoadjuvant atezolizumab.1 Dr. Herbst led...
Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis
The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...
Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, invites his colleagues to enroll their patients in a large prospective study, for which he serves as Principal Investigator. The study is searching for solutions for treating patients with lung cancer who also have the coronavirus, because so...
Expert Point of View: John C. Krauss, MD
Invited discussant John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, said he was impressed by the “rapidity with which the NRG-GI002 trial accrued,” which was about 10 months.1 “Equally...
David Fajgenbaum, MD, MBA, on Repurposing Cancer Drugs to Treat COVID-19
David Fajgenbaum, MD, MBA, of the University of Pennsylvania, talks about his research efforts to find an already-approved drug that could treat his orphan disease—multicentric Castleman disease—and how that methodology may be applied to the coronavirus and the cytokine storm it can cause...
Study Identifies Mechanisms Tied to Immunotherapy Resistance Among Patients With Melanoma
Researchers have created a new technique that may help to uncover mechanisms cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. Investigators tested their new technique with cancer cells and matching immune cells from patients with melanoma...
Preclinical Research Shows Activity of Fidaxomicin Combination Therapy in MLL-AML
A specific type of acute myeloid leukemia (AML) that contains a rearrangement in the MLL gene (also known as KMT2A) might be made more sensitive to chemotherapy using an antibiotic currently available to treat diarrhea, according to new research published by Zeisig et al in Science Translational...
Updates From Selected Clinical Trials in Breast Cancer
Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his picks of the most important and most clinically relevant research presented at this meeting. The following are summaries of studies that caught Dr. Abraham’s attention from ...
In Case You Missed It: Brief Highlights From ASH 2020
In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of meeting coverage. Many of these reports are on early-phase clinical trials of agents that may raise...
IASLC Honors Pan-Chyr Yang, MD, PhD, for Contributions to Lung Cancer Prevention
Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan, received the Joseph W. Cullen Prevention/Early Detection Award from the International Association for the Study of Lung Cancer (IASLC) at the virtual IASLC 2020 World...
Professor Gordon McVie, International Cancer Researcher and Patient Advocate, Dies at 76
An imposing painting of sailing ships graced the wall behind the desk in the office of Professor Gordon McVie, BSc (Hons), MBChB, MD, FRCP, FRCPEd, FRCPS (Glas), FMedSci, DSc. It was a gift from one of his patients with cancer, a long-term survivor who said the painting reminded her of him, walking ...
John Bartlett, MD, Pioneer in Infectious Diseases Research and Treatment, Dies at 83
John Bartlett, MD, a visionary physician-scientist and pioneer in HIV/AIDS study and treatment who built the infectious diseases division at The Johns Hopkins, died on January 19, 2021, in New York. He was 83 years old. “Over his long and illustrious career, John Bartlett epitomized the best of...
Gert Brieger, MD, MPH, PhD, Historian of Medicine and Public Health, Dies at 89
Gert Brieger, MD, MPH, PhD, former Director of the Johns Hopkins University School of Medicine Institute of the History of Medicine, died on January 13, 2021, due to heart failure. He was 89. Dr. Brieger is credited with transforming the department from a research center with occasional students to ...
Joseph V. Simone, MD, Visionary Pediatric Oncologist and ‘Quintessential Mentor,’ Dies at 85
When Joseph V. Simone, MD, was 6 years old, he had his first experience with the death of a child. His 9-month-old brother became sick with the croup and was taken to the nearby children’s hospital, where he died a few days later, leaving Dr. Simone and his family devastated. Caring for sick...
Conversations With the Pioneers of Oncology: Emil J Freireich, MD, FASCO
To hear an interview with Dr. Freireich by Daniel F. Hayes, MD, FASCO, of the University of Michigan Rogel Cancer Center and Past President of ASCO, visit the Journal of Clinical Oncology’s podcast, Cancer Stories, wherever you get your podcasts. In this episode, the Cancer Stories podcast reflects ...
Oncology Community Mourns the Death of Chemotherapy Pioneer Emil J Freireich, MD, FASCO
Legendary oncologist Emil J Freireich, MD, FASCO, died from COVID-19 on February 1, 2021, at The University of Texas MD Anderson Cancer Center in Houston, where he had worked for 50 years. He was 93. During a career that spanned more than 6 decades, Dr. Freireich was relentless in pursuing cures...
United States Surpasses 500,000 Deaths Due to COVID-19
On February 22, President Joseph R. Biden issued remarks to proclaim that over 500,000 Americans have now died from COVID-19 infection. He and Vice President Kamala Harris held a moment of silence and ordered flags be lowered to half-mast at federal buildings for the next 5 days to honor those who...
Prognostic Tool RSClin Introduced for Early Breast Cancer
Data from the TAILORx study and several National Surgical Adjuvant Breast and Bowel Project (NSABP) trials have been used to develop a new prognostic tool, RSClin, which aims to individualize the estimate of recurrence risk in early breast cancer and to more accurately predict the risk-reduction...
Chemotherapy-Induced ‘Dormancy’ in AML Allows Cancer Cell Survival, May Contribute to Relapse
Researchers have identified a cellular resilience mechanism through which acute myeloid leukemia (AML) cells survive cancer treatment and repopulate, leading to disease relapse. The research, published by Cihangir Duy, PhD, MS, and colleagues in Cancer Discovery, also suggests that certain drugs...
Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome
Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...
Joint ASCO/ACS CAN Letter: States Must Include Patients With Cancer on Their COVID-19 Vaccine Priority Lists
In the midst of growing concerns that patients with cancer have limited access to the COVID-19 vaccines, the Association for Clinical Oncology (ASCO) and American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society, issued a joint letter to every...
Fecal Microbiota Transplants May Help Patients With Advanced Melanoma Respond to Immunotherapy
For patients with melanoma who do not respond to treatment with immunotherapy, adjusting the composition of microorganisms in the intestines through the use of fecal transplants may aid in overcoming resistance to therapy. These findings were published by Davar et al in Science. In the study, some...
Genetic Mutations Linked to Worse B-Cell ALL Outcomes in Pediatric Hispanic and Latino Patients
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino patients, according to a new study published by Raca et al in the journal Leukemia. Researchers said a novel therapeutic drug combination—as well as testing for...
ASCO Congratulates Joseph R. Biden, Jr, on Presidential Inauguration
“On the eve of his inauguration, the Association for Clinical Oncology (ASCO) congratulates Joseph R. Biden, Jr, the 46th President of the United States. “ASCO shares the President’s commitment to ensuring equitable high-quality cancer care for every American, and recently released a policy...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Vanderbilt University Medical Center Appoints Interim Director of the Division of Hematology and Oncology
Ben Ho Park, MD, PhD, Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, has been named Interim Director of the Division of Hematology and Oncology. Dr. Park is Associate Director for Translational Research, Co-Leader of the Breast Cancer Research Program,...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
Miami Cancer Institute Appoints New Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology
Neuro-oncologist and medical oncologist Manmeet Ahluwalia, MD, FACP, MBA, has joined Miami Cancer Institute as Deputy Director, Chief Scientific Officer and Chief of Solid Tumor Medical Oncology. Board-certified in internal medicine, medical oncology, neuro-oncology and hematology, Dr. Ahluwalia...
Bruce E. Johnson, MD, on Evolving Challenges in Lung Cancer Drug Development
Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biomarker testing, and the societal costs of drug development (Abstract PL04.03).
Understanding Patients’ Needs and Preferences: Cancer Care Stakeholders Explore Barriers and Best Practices
The keynote speaker did not mince words. “I tell everyone, do not use the term age-appropriate therapy,” said Jan White, a cancer survivor and patient advocate who described her own experience with stage IV non-Hodgkin lymphoma. “Patients with cancer,” she said, “are more than their age, gender,...
